Autres langues Takeda Pharmaceutical Company Limited NYSE

Actions

TAK

US8740602052

Produits pharmaceutiques

Temps réel estimé Cboe BZX 16:26:24 25/08/2026			Varia. 5j.	Varia. 1 janv.
18,30 ^USD	+0,33%		+1,22%	+17,19%

24/08	La FDA suspend les essais cliniques de la thérapie génique de Regenxbio contre le syndrome de Hunter	RE
24/08	Takeda : l'Orzeryful approuvé au Japon, premier traitement ciblant la narcolepsie de type 1	MT

Autres langues

24/08	Takeda Pharmaceutical : Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn)
24/08	FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
24/08	Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1
24/08	Takeda Pharmaceutical Company Limited Receives Approval For Orzeyful (Oveporexton) To Treat Narcolepsy Type 1 In Japan
24/08	Takeda Secures Japan Approval for Orzeyful to Treat Narcolepsy Type 1
24/08	ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
18/08	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
13/08	Takeda Pharmaceutical Insider Sold Shares Worth $1,523,439, According to a Recent SEC Filing
13/08	Takeda Pharmaceutical Insider Sold Shares Worth $2,828,220, According to a Recent SEC Filing
06/08	Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL
06/08	Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1
06/08	U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
05/08	US FDA approves Takeda's sleep disorder pill
05/08	Takeda Pharmaceutical Seeks India's Backing for Landmark Dengue Shot
30/07	Keros Therapeutics to Receive $20 Million Development Milestone Payment From Takeda
30/07	Takeda Pharmaceutical Company Limited Provides Impairment of Intangible Assets Guidance for the Fiscal Year ending March 31, 2027
30/07	Takeda Pharmaceutical Profit Drops 9% in Fiscal Q1
30/07	Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Rise
30/07	Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year Ending March 31, 2027
30/07	Takeda Quarterly Profit Weakens, Backs Annual Guidance
30/07	Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2026 q1 er en)
30/07	Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
30/07	Takeda Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
27/07	China's Innocare says psoriasis oral drug shows 'consistent treatment effect' in late-stage trial